Winship Cancer Institute Cancer Center Support Grant

项目概要/摘要 埃默里大学温希普癌症研究所（Winship）是格鲁吉亚唯一一家NCI指定的癌症中心， 该州现在是美国人口第八多的州，在密西西比河以东各州中拥有最大的土地面积 河作为该州主要的三级癌症护理和癌症研究机构，Winship致力于 四个研究计划，由其六个共享资源支持，以解决相关的具体挑战 格鲁吉亚的癌症负担。这些挑战包括：高烟草使用率和吸烟率- 相关癌症;非裔美国人或黑人和/或有显著 癌症在护理、预后和/或结果方面的差异问题;以及健康素养水平低。Winship的使命 是为了减轻格鲁吉亚公民的癌症负担，格鲁吉亚是其主要的集水区。这将是完成 通过：（1）寻求对癌症的分子，遗传和表观遗传基础的更深入的了解;（2）发现新的 推动癌症检测、预防和/或治疗改进的知识;（3）开发或定义 新的治疗靶点和/或药物作为更好的癌症治疗途径;和（4）研究和 实施基于人口的战略，以减轻该州的癌症负担。164 Winship核心 成员积极参与四个Winship研究项目之一，所有这些项目都非常强调 跨学科研究：癌症细胞生物学，癌症遗传学和表观遗传学，癌症预防和 控制、发现和发展治疗学。Winship的成员由六个共享的 资源：生物统计学和生物信息学共享资源，癌症动物模型共享资源，癌症 组织和病理学共享资源，埃默里综合基因组学共享资源，埃默里综合 蛋白质组学共享资源和综合成像共享资源;以及两个开发共享资源 资源：Winship研究信息学和干预发展，传播和实施 开发共享资源。Winship成员目前获得了8480万美元的研究资金 (as 3/31/2016）通过埃默里大学授予。Winship成员Curran和Bruner担任两个NCI的PI 授予NRG肿瘤学基金会总计2560万美元，用于支持临床研究基础设施。 Winship的干预性和非干预性试验的患者入组人数继续增加，特别是 在代表性不足的少数群体的患者中，这些活动有助于FDA- 在目前的资助期间，批准了几种新的抗癌药物。Winship拥有出色的 机构承诺，承诺在今后五年提供2亿多美元的机构支助， 几乎是2011年承诺的两倍。Winship享有相同的报告线和组织地位 埃默里医学院、公共卫生学院和护理学院。Winship的独特定位是将其科学的 优势，杰出的成员，强大的基础设施，强大的机构支持，以及全面的 培训计划，以履行其使命，减轻癌症的负担，对格鲁吉亚和超越国家。

PROJECT SUMMARY/ABSTRACT The Winship Cancer Institute of Emory University (Winship) is the only NCI-designated cancer center in Georgia, which is now the eighth most populous state and has the largest land area among states east of the Mississippi River. As the main tertiary cancer care and cancer research institution in the state, Winship has committed its four research programs as supported by its six shared resources to address the specific challenges associated with the cancer burden in Georgia. These challenges include: high tobacco usage and incidence of tobacco- related cancers; high proportion of cancer patients who are African American or black and/or have significant cancer disparity issues in their care, prognosis, and/or outcome; and low health literacy levels. Winship's mission is to lessen the burden of cancer for the citizens of Georgia, its primary catchment area. This will be accomplished by: (1) seeking greater insights into the molecular, genetic, and epigenetic basis of cancer; (2) discovering new knowledge that drives improvements in cancer detection, prevention, and/or therapy; (3) developing or defining novel therapeutic targets and/or agents as a pathway to better cancer therapies; and (4) studying and implementing population-based strategies to lessen the cancer burden in the state. The 164 Winship core members are actively engaged in one of four Winship research programs, all of which have a strong emphasis on transdisciplinary research: Cancer Cell Biology, Cancer Genetics and Epigenetics, Cancer Prevention and Control, and Discovery and Developmental Therapeutics. Winship's members are supported by six shared resources: Biostatistics and Bioinformatics Shared Resource, Cancer Animal Models Shared Resource, Cancer Tissue and Pathology Shared Resource, Emory Integrated Genomics Shared Resource, Emory Integrated Proteomics Shared Resource, and the Integrated Imaging Shared Resource; and two developing shared resources: Winship Research Informatics and Intervention Development, Dissemination, and Implementation Developing Shared Resources. Winship members are currently supported by $84.8M in total research funding (as of 3/31/2016) awarded via Emory University. Winship members Curran and Bruner serve as PIs on two NCI awards to the NRG Oncology Foundation for a total of $25.6M in support of clinical research infrastructure. Patient enrollment in Winship's interventional and non-interventional trials continues to increase, especially among patients from under-represented minority groups, and these activities have contributed to the FDA- approval of several novel anti-cancer agents during the present funding period. Winship has outstanding institutional commitment, with more than $200 million in institutional support committed over the next five years, a level almost twice that committed in 2011. Winship enjoys the same reporting line and organizational position as Emory's schools of medicine, public health, and nursing. Winship is uniquely positioned to apply its scientific strengths, outstanding membership, robust infrastructure, strong institutional support, and comprehensive training programs to fulfill its mission of lessening the burden of cancer on the state of Georgia and beyond.